New Technologies and Advances in Infection Prevention (A Marr, Section Editor)

# Using New Technology to Prevent Healthcare-Associated Infection in Pediatric Patients

Claudio Schvartsman, PhD<sup>1</sup> Daniela Nasu Monteiro Medeiros, MD<sup>1,2,\*</sup> Eduardo Juan Troster, PhD<sup>1</sup>

#### Address

\*<sup>1</sup>Hospital Israelita Albert Einstein, Avenida Albert Einsten, 627/701, Morumbi, São Paulo, SP, 05652-900, Brazil Email: daninasu@gmail.com
<sup>2</sup>Hospital Municipal Moysés Deutsch—M'Boi Mirim, Estrada do M'Boi Mirim, 5203, Jardim Angela, São Paulo, SP, Brazil

Published online: 2 February 2016 © Springer Science+Business Media New York 2016

This article is part of the Topical Collection on *New Technologies and Advances in Infection Prevention* 

Keywords Healthcare-associated infection · Pediatric patients · Technology

#### **Opinion statement**

Healthcare-associated infections have a great impact in patients' morbidity and mortality, as well as increasing the length of stay in the hospital and treatment costs. Progresses in the study of epidemiologic health care and researches in its implementation have led to a better comprehension of the effective strategies to prevent the foresaid infections. The objective of this study is to present and discuss the technological innovations in the prevention of healthcare-associated infections. The following data bases were accessed: PUBMED, EMBASE, Scielo, Scopus, and Cochrane, using the key words: healthcareassociated infections, prevention, innovations, innovative, ventilator-associated pneumonia (VAP), catheter-related bloodstream infection (CRBSI). The evidence degree from the Canadian Task Force on Preventive Health Care was used. For every item, the recommendation degree from the Society for Healthcare Epidemiology of America (SHEA/IDSA) was used. Telemedicine, computerized training, realistic training, hand hygiene monitoring technology, chlorhexidine bathing, chlorhexidine-impregnated dressings, antimicrobial-impregnated catheters, high-flow nasal cannula, subglottic aspiration cannula, and silver-coated endotracheal tubes are examples of the new technologies discussed in the article. However, they do not replace cultural measures, such as the healthcare team's education, the establishment and compliance to protocols, and multidisciplinary visits where the need for devices and mechanical ventilation is questioned.



#### Introduction

Healthcare-associated infections (HAI) have a great impact in patients' morbidity and mortality, as well as increasing the length of stay in the hospital and treatment costs [1–5].

There are various aspects that healthcare-associated infections and infection control interventions have an impact: hospitalization costs (antibiotics, excess length of stay, and intensive care stay), intervention costs (tests costs, gown and glove, nurse and physician time, isolation room), outpatient expenses (physician visits, antibiotics, home health visits, rehabilitation center stay), and patient expenses and outcomes (mortality, morbidity, infections, lost wages, travel expenses) [6].

There is a large body of literature, which has shown that

HAI are one of the major causes of patient morbidity and mortality in industrialized countries. Device-associated infections, such as ventilator-associated pneumonia, central venous catheter-associated bloodstream infection, and catheter-associated urinary tract infection have the greatest challenge to hospital safety and quality healthcare in intensive care unit [7].

Progresses in the study of epidemiologic health care and researches in its implementation have led to a better comprehension of the effective strategies to prevent the foresaid infections [8••].

In spite of these advances, there is a great interval between the recommendations and the clinical practices [8••].

<b>Opinion statement</b>	
	Healthcare-associated infections have a great impact in patients' morbidity and mortality as well as increasing the length of hospital stay and the treatment costs. New technologies for the prevention of healthcare-associated infections need to be combined with cultural measures such as the healthcare team's education, the establishment and compliance to protocols and multidisciplinary visits.
Objective	
	The objective of this study is to present and discuss the technological innova- tions in the prevention of healthcare-associated infections.
Methods	
	The following data bases were accessed: PUBMED, EMBASE, Scielo, Scopus, and Cochrane, using the key words: health-related infections, prevention, innova- tions, innovative, ventilator-associated pneumonia (VAP), and catheter-related bloodstream infection (CRBSI). The evidence degree from the Canadian Task Force on Preventive Health Care was used. For every item, the recommendation degree from the Society for Healthcare Epidemiology of America (SHEA/IDSA) was used [8••].
New technologies for the pr	evention of health-related infections
Telemedicine	Telemedicine is defined as the provision of long-distance health care, using the

Telemedicine is defined as the provision of long-distance health care, using the telecommunication technology [9].

Lilly et al. studied seven adult intensive care units, with the objective of quantifying the association of telemedicine in mortality, length of stay, complications, and greater compliance to the best clinical practices. The authors observed greater compliance to clinical practices and prevention of VAP, less incidence of VAP, less rates of CRBSI, and shorter length of stay [10]. Later, the same authors studied 56 ICUs and observed better compliance to medical practices after the use of telemedicine [11].

#### Training (evidence degree II)

Computerized training (e-learning) can be used as a tool to promote training and education, as traditional methods have their limitations in reaching professionals [12]. Its advantages would be the flexibility in time and physical location to access it [13]. Comer et al. applied some pre- and post-tests with elearning-related questions and observed a greater understating about the risk of CRBSI [14].

Another training option is realistic simulation. Barsuk et al. observed a decrease in CRBSI rates in the unit where the realistic simulation training for central catheter insertion took place. In the unit where this training method was used, the incidence of infection was 0.5 infections/1000 catheter-days. Prior to its implementation, the rate at this unit was 3.2/1000 catheter-days, and in other units that did not use this technology, the rate was 5.03/1000 catheter-days [15].

Khouli et al. studied realistic simulation for central line insertion involving 47 medical residents. They observed a 70 % decrease in the incidence of CRBSI in the group that used the simulation.

#### Hand hygiene (evidence degree II)

It is extremely important to avoid *Clostridium dificille*-related diseases [8].

Hand hygiene monitoring technology is a potential solution for poor healthcare worker hand hygiene compliance [16, 17]. This technology includes systems that count alcohol-based hand rub or soap dispensing events and complex systems that stimulate the compliance in real time, video cameras, dedicated hand hygiene monitoring systems, and real-time location systems.

Evidence suggests that electronic monitoring is not more accurate than direct observation, but it is related to an improved practice.

Electronic monitoring provides objective information that can be used as feedback with the health professionals. However, this information can be used in a dangerous and unproductive way [16, 18].

The success of these technologies depends on the physical structure and organizational culture of the implementing unit. The success of feedback depends on who provides it and the medium used (e.g., email or face to face meeting) and the specific content, as it can influence the team work culture [18]. Recommendation evidence to provide feedback is degree III [8••].

#### Chlorhexidine bathing (evidence degree I)

Chlorhexidine bathing is recommended for patients over 2 months of age to prevent catheter-related blood stream infections [8••].

Chlorhexidine gluconate (CHG) is a topical antiseptic that inhibits

organism growth and reduces skin colonization [21]. CHG presents a broadspectrum activity against *Staphylococcus aureus* and *Enterococcus* species, as it has a residual antibacterial activity [19•]. As hospital-acquired bloodstream infections are often caused by skin organisms, skin decontamination would prevent these infections.

Chlorhedixine bathing is a safe and simple option to prevent the transmission of resistant microorganisms and to decrease hospital-acquired infections [19•, 20]. Milstone et al. conducted a study in children in intensive care units, where they presented a lower incidence of bacteremia and the treatment was well tolerated [21].

Chen et al. did a meta-analysis review of 12 articles in adult patients. Four of them showed a reduction in the risk of infection due to methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE), a decrease in MRSA infections and in MRSA ventilator-associated pneumonia. As for VRE, skin colonization and infections were reduced [22].

Popp et al. studied 203 thermally injured patients. The median burn area was 25 % of total body surface area. They observed a significant reduction in ventilator-associated pneumonia, catheter-related bloodstream infections, and catheter-associated urinary tract infections [23].

Milstone et al. studied 4947 pediatric patients, older than 2 months, who received daily chlorhexidine bathings. The treatment was well tolerated by the patients. Those who received daily chlorhexidine bathings and had central venous catheters (CVC), showed a 34 % decrease in the risk of bacteremia. The incidence of CRBSI was less in the chlorhexidine group, but without a statistical significance difference [21].

## Utilization of chlorhexidine-impregnated dressings to occlude central venous catheter in patients older than 2 months (evidence degree I)

A new chlorhexidine-impregnated dressing was developed (Biopatch®; Johnson & Johnson). Two studies observed a reduction in the colonization of the catheter insertion sites and a 60 % reduction of CRBSI. No resistance to chlorhexidine or adverse reactions was observed [24, 25].

Garland et al. studied 703 patients from 6 neonatal intensive care units. One group received a povidone-iodine skin scrub, and the other a 70 % alcohol scrub followed by placement of a chlorhexidine-impregnated disk over the catheter insertion site. The antimicrobial dressing group had less colonization of CVC tips. Rates of CRBSI and blood stream infections (BSI) without a source did not differ between the two groups. Localized contact dermatitis from the antimicrobial dressing occurred in 15.3 % of the neonates weighing  $\leq 1000$  g [26].

## Utilization of antimicrobial-impregnated catheters (evidence degree I for adults; evidence degree II for children)

The use of antimicrobial-impregnated catheters is based on the concept of the skin origin of bacteremia [27, 28].

Lai et al. conducted a meta-analysis of 56 studies in adults, with 11 different types of antimicrobial impregnations. Catheter impregnation reduced catheter colonization, but made no statistically significant difference to the rates of

sepsis and all-cause mortality. There were also no statistically significant differences between the groups regarding the rates of adverse effects, including thrombosis/thrombophlebitis, bleeding, erythema, and/or tenderness at the insertion site [29].

There is only one pediatric study, with 98 preterm infants, where a silverimpregnated umbilical catheter was used, and a reduction in CRBSI was observed.

Antimicrobial-impregnated catheters are recommended to prevent CRBSI in adults and the recommendation degree II for children derives from this [8••].

#### High-flow nasal cannula

Guidelines for VAP recommend that intubation should be avoided using noninvasive ventilation, with a recommendation degree I [8••, 30••]. High-flow nasal cannula (HFNC) could be an alternative to non-invasive ventilation.

Over the last decade, high-flow nasal cannula has increasingly been used in neonatology, gradually replacing nasal continuous positive airway pressure (CPAP) [31].

HFNC administers a heated and humidified mixture of air and oxygen at a higher flow than the patient's inspiratory flow. HFNC diminishes the resistance in the nasal mucosa, "washes out" the gas from the dead space, and creates a 6-cm  $H_2O$  pharyngeal pressure. This results in greater comfort and oxygenation for the patient [31].

High-flow nasal cannula can be an alternative to non-invasive ventilation due to a greater tolerance to the interfaces and a lesser need for sedatives [32].

There are still few pediatric studies showing an improvement in respiratory distress and a better oxygenation. However, meta-analysis has not yet demonstrated a statistically significant improvement [32, 33].

#### Subglottic aspiration cannula (evidence degree III for children and II for adults)

With the insertion of the endotracheal tube, secretions are easily drained and accumulated in the subglottic space. This contaminated secretion slides along the tube and contributes to the occurrence of pneumonia. Therefore, the constant or intermittent aspiration of this secretion could be a strategy [34]. Studies indicate a reduction in VAP in approximately 50 %, reduction in the use of mechanical ventilation, and in the length of stay in intensive care units (ICU). However, there is no evidence of the reduction in mortality.

The obstacles for using subglottic aspiration cannula are its cost, in average, 10 times higher, and also the risk of tracheal injury, with the possibility of a tracheoesophageal fistula and post-extubation laryngitis [34].

Studies were done with adult patients, and the limitations for its use in younger children is the size of the available cannula (size 6 and over), which is indicated for children older than 10 years  $[30 \bullet \bullet]$ .

#### Utilization of silver-coated endotracheal tubes

An effective strategy to reduce VAP is to treat the endotracheal tube with an antiseptic agent to control the formation of biofilm. Biofilm is the bacterial adherence to objects, covered by an exopolysaccharide matrix, which makes it resistant to antibiotic penetration [35]. Biofilm lining is more evident in the distal third of the endotracheal tube and can be formed in the first 60 h of intubation [36].

Silver has antimicrobial properties, and in vitro studies revealed a milder colonization by *S. aureus* and *Pseudomonas aeruginosa* [37, 38].

The recommendations are derived from those in adult patients [30••].

In a meta-analysis, Tokmaji et al. reviewed three randomized controlled trials with a total of 2081 participants. The "risk of bias" assessment indicated a high risk of bias due to lack of blinding of outcomes assessors. There is limited evidence that silver-coated endotracheal tubes reduce the risk of VAP, especially during the first 10 days of mechanical ventilation [39].

There is still no recommendation for this technology.

## Conclusions

New technologies are important advances in the prevention of healthcareassociated infections. They are new tools. However, they do not replace cultural measures, such as the healthcare team education, the establishment and compliance to protocols, and multidisciplinary visits where the need for devices and mechanical ventilation is questioned.

### **Compliance with Ethical Standards**

#### **Conflict of Interest**

Dr. Schvartsman declares that he has no conflict of interest.

- Dr. Medeiros declares that she has no conflict of interest.
- Dr. Troster declares that he has no conflict of interest.

#### Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

### **References and Recommended Reading**

Papers of particular interest, published recently, have been highlighted as:

Of importance

- •• Of major importance
- 1. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest. 1991;100(1):164–7.
- Collignon PJ. Intravascular catheter associated sepsis: a common problem. Med J Aust. 1994;161:374–8.
- Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheterrelated septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol. 1999;20(6):396–401.
- 4. Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary

nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med. 1999;160(3):976–81.

- Rello J, Ochagavia A, Sabanes E, et al. Evaluation of outcome of intravenous catheter related infections in critically ill patients. Am J Respir Crit Care Med. 2000;162:1027–30.
- Cosgrove SE, Perencevich EN. Economic evaluation of healthcare-associated infections and infection control interventions. In: Jarvis WR, editor. Bennett & Brachman's hospital infections. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2007. p. 235–46. Chapter 16.

- Lynch P, Rosenthal VD, Borg MA, Eremin SR. Infection control: a global view. In: Jarvis WR, editor. Bennett & Brachman's hospital infections. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2007. p. 255–71. Chapter 18.
- 8.•• Yokoe DS, Anderson DJ, Berenholtz SM, Calfee DP, Dubberke ER, Ellingson KD, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. Infect Control Hosp Epidemiol. 2014;35(8):967–77. doi:10.1086/677216.

These articles are the basis of degrees of evidence.

- 9. Marcin JP. Telemedicine in the pediatric intensive care unit. Pediatr Clin N Am. 2013;60:581–92. doi:10. 1016/j.pcl.2013.02.002.
- Lilly CM, Cody S, Zhao H, et al. Hospital mortality, length of stay, and preventable complications among critically Ill patients before and after tele-ICU reengineering of critical care processes. JAMA. 2011;305(21):2175–83. doi:10.1001/jama.2011.697.
- 11. Lilly CM, McLaughlin JM, Zhao H, et al. A multicenter study of ICU telemedicine reengineering of adult critical care. Chest. 2014;145(3):500–7.
- Bouza E, Pérez MJ, Muñoz P, Rincón C, Barrio JM, Hortal J. Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the post-operative period of major heart surgery. Chest. 2008;134(5):938–46.
- 13. Cook DA. Web-based learning: pros, cons and controversies. Clin Med. 2007;7(1):37–42.
- Comer A, Harris AD, Shardell M, Braun B, Belton BM, Wolfsthal SD, et al. Web-based training improves knowledge about central line bloodstream infections. Infect Control Hosp Epidemiol. 2011;32(12):1219– 22.
- Barsuk JH, Cohen ER, Feinglass J, McGaghie WC, Wayne DB. Use of simulation-based education to reduce catheter-related bloodstream infections. Arch Intern Med. 2009;169(15):1420–3.
- Boyce JM. Measuring healthcare worker hand hygiene activity: current practices and emerging technologies. Infect Control Hosp Epidemiol. 2011;32:1016e1028.
- 17. Marra AR, Edmond MB. Hand hygiene: state-of-the-art review with emphasis on new technologies and mechanisms of surveillance. Curr Infect Dis Rep. 2012;14:585e591.
- Srigley JA, Gardam M, Fernie G, Lightfoot D, Lebovic G, Muller MP. Hand hygiene monitoring technology. J Hosp Infect. 2015;89:51e60.
- Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368(6):533–42. doi:10.1056/NEJMoa1113849.

This article is the first article to discuss the effect of daily chlorhexidine bathing on hospital-acquired infection, on a great number of patients.

 Sievert D, Armola R, Halm MA. Chlorhexidine gluconate bathing: does it decrease hospitalacquired infections? Am J Crit Care. 2011;20(2):166–70.

- Milstone AM, Elward A, Song X, Zerr DM, Orscheln R, Speck K, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013;38(9872):1099–106. doi:10.1016/S0140-6736(12)61687-0.
- Chen W, Li S, Li L, Wu X, Zhang W. Effects of daily bathing with chlorhexidine and acquired infection of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: a meta-analysis. J Thorac Dis. 2013;5(4):518–24. doi:10.3978/j.issn. 2072-1439.2013.08.30.
- Popp JA, Layon AJ, Nappo R, Richards WT, Mozingo DW. Hospital-acquired infections and thermally injured patients: chlorhexidine gluconate baths work. Am J Infect Control. 2014;42(2):129–32. doi:10.1016/ j.ajic.2013.08.015.
- 24. Hanazaki K, Shingu K, Adachi W, Miyazaki T, Amano J. Chlorhexidine dressing for reduction in microbial colonization of the skin with central venous catheters: a prospective randomized controlled trial. J Hosp Infect. 1999;42(2):165–8.
- 25. Maki DG, Mermel LA, Kluger DM, et al. The efficacy of a chlorhexidine-impregnated sponge (biopatch) for the prevention of intravascular catheter-related infection: a prospective, randomized, controlled, multicenter trial [abstract 1430]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Ontario). Washington, DC: ASM Press; 2000:422.
- Garland JS, Harris MC, Alex CP, et al. A randomized trial comparing povidone-iodine to chlorhexidine gluconate impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics. 2001;107(6):1431–6.
- 27. Moro ML, Vigano EF, Cozzi Lepri A. Risk factors for central venous catheter-related infections in surgical and intensive care units. The central venous catheter-related infections study group. Infect Control Hosp Epidemiol. 1994;15:253–64.
- Safdar N, Maki DG. The pathogenesis of catheterrelated bloodstream infection with noncuffed shortterm central venous catheters. Intensive Care Med. 2004;30:62–7.
- Lai NM, Chaiyakunapruk N, Lai NA, O'Riordan E, Pau WS, Saint S. Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults. Cochrane Database Syst Rev. 2013;6:CD007878. doi:10.1002/14651858. CD007878.pub2.
- 30.•• Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(8):915–36. doi:10.1086/677144.
- These articles are the basis of degrees of evidence.
- 31. Milési C, Boubal M, Jacquot A, Baleine J, Durand S, Odena MP, et al. High-flow nasal cannula: recommendations for daily practice in pediatrics. Ann

Intensive Care. 2014;4:29. doi:10.1186/s13613-014-0029-5. eCollection 2014.

- 32. Mayfield S, Jauncey-Cooke J, Hough JL, Schibler A, Gibbons K, Bogossian F. High-flow nasal cannula therapy for respiratory support in children. Cochrane Database Syst Rev. 2014; Issue 3. Art. No.: CD009850. doi: 10.1002/14651858.CD009850.pub2.
- Beggs S, Wong ZH, Kaul S, Ogden KJ, Walters JAE. High-flow nasal cannula therapy for infants with bronchiolitis. Cochrane Database Syst Rev. 2014, Issue 1. Art. No.: CD009609. doi: 10.1002/14651858. CD009609.pub2.
- Haas CF, Eakin RM, Konkle MA, Blank R. Endotracheal tubes: old and new. Respir Care. 2014;59(6):933–52. doi:10.4187/respcare.02868. discussion 952–5.
- 35. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–22.

- Feldman C, Kassel M, Cantrell J, et al. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur Respir J. 1999;13(3):546–51.
- Pacheco-Fowler V, Gaonkar T, Wyer PC, et al. Antiseptic impregnated endotracheal tubes for the prevention of bacterial colonization. J Hosp Infect. 2004;57(2):170–4.
- Rello J, Kollef M, Diaz E, et al. Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Crit Care Med. 2006;34:2766–72.
- Tokmaji G, Vermeulen H, Müller MCA, Kwakman PHS, Schultz MJ, Zaat SAJ. Silver-coated endotracheal tubes for prevention of ventilator associated pneumonia in critically ill patients (review). Cochrane Database Syst Rev. 2015;8:CD009201. doi:10.1002/14651858. CD009201.pub2.